Saturday 17 October 2026
Export CTXR’s income statement to Excel — free account
Citius Pharmaceuticals, Inc.
CTXR Healthcare Biotechnology
In the quarter to June 2026, EPS grew 57.5% and free cash flow fell 60.5%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
0.46
0.00
0.00%
Follow CTXR
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (64.51%) | (69.65%) | (44.20%) | (49.38%) |
+8 more TTM periods Free account |
|
| (34.29%) | (36.38%) | (27.49%) | (30.24%) | ||
ROIC |
(58.74%) | (56.63%) | (27.34%) | (32.86%) | |
Return on Tangible Assets |
556.31% | 198.03% | 13,697.14% | 220.46% | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | — | |
Free Cash Flow per Share |
(1.33) | (1.41) | (1.62) | (2.40) | |
Free Cash Flow |
(34.87) | (31.60) | (34.84) | (26.55) | |
| Other line items | |||||
Cash ROIC |
(35.10%) | (42.89%) | (34.43%) | (32.47%) | |
Accounts Payable Turnover |
0.18 | 0.13 | 0.10 | 0.00 | |
Inventory Turnover |
0.08 | 0.06 | 0.05 | 0.00 | |
Average Days of Payables |
1,767.48 | 2,835.13 | 4,296.50 | 0.00 | |
Days of Inventory on Hand |
4,975.27 | 6,795.46 | 8,825.53 | 0.00 | |
Tax Rate |
0.00 | 0.01 | 0.03 | 0.03 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(119.03) | (128.07) | (50.13) | (41.45) | |
Operating CF/Net income |
0.75 | 0.68 | 0.97 | 0.71 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.33) | (1.41) | (1.62) | (2.40) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates